Epinoma develops a CRISPR-based epigenetic blood test that detects early signs of cancer and neurodegenerative diseases, providing a more precise alternative to traditional imaging and protein marker methods. This technology enhances patient stratification strategies in clinical settings, enabling oncologists to make informed decisions for late-stage colorectal cancer patients.
Funding
$130K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting early signs of cancer and neurodegenerative diseases rely on traditional imaging and protein marker methods, which can be imprecise. Existing approaches for studying methylation, a key epigenetic driver for diseases, often depend on noisy methods that rely on sequence conversion and degradation.
Solution
Epinoma is developing a CRISPR-based epigenetic platform for diagnostics and therapeutics. Their technology focuses on analyzing and modulating epigenetic marks, specifically methylation, to improve disease detection and treatment. By comparing healthy and diseased epigenetic states, Epinoma aims to provide insights into drug development and enable more effective patient stratification strategies in clinical settings. The platform offers a new approach for precision epigenetic medicine by altering the epigenetic status of genes, while keeping the genomic sequences unchanged.
Target Audience
Epinoma's primary customers include biopharma companies seeking to accelerate drug development and oncologists looking for more effective patient stratification strategies.
Features
- Protein engineering platform for building epigenetic-driven diagnostics and therapeutics
- Analysis of methylation patterns in blood for early disease detection
- CRISPR-based technology for precise epigenetic modification
- Tools for screening and selecting promising pre-clinical compounds